Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc's positive outlook is supported by significant revenue growth, with Q3 revenue reported at $18,942, reflecting a 31% increase year-over-year, driven by an impressive 89% rise in Nociscan report volumes. The company's ongoing momentum is further evidenced by the successful enrollment of commercial agreements with notable healthcare institutions, which is anticipated to enhance the adoption of their Nociscan platform. Additionally, Aclarion's proactive investment in sales and marketing, evidenced by a 172% year-over-year increase in related expenses, indicates a strategic commitment to expanding market presence and supporting clinical trial initiatives.

Bears say

Aclarion Inc faces a challenging financial outlook primarily due to slower-than-expected market traction with both surgeons and payers, which jeopardizes the growth potential of its Nociscan product. The company has consistently revised its FY25 earnings per share (EPS) estimates downward, with projections now reaching as low as $(15.13) due to mounting operating expenses that exceed earlier forecasts. Additionally, significant risks related to liquidity, regulatory approvals, reimbursement issues, and competitive pressures further complicate the company’s ability to achieve its commercial objectives and stabilize financial performance.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.